About Mercy

News Archive

Media Contact: 
Aaron Scheinblum, Communication Strategist
319-358-2627 or e-mail: aaron.scheinblum@mercyic.org

Tuesday, April 6, 2021 - Mercy Iowa City Urology to host virtual Men’s Health Seminar, partnering with UroLift

Mercy Iowa City Urology has partnered with UroLift to host a virtual Men’s Health Seminar. Mercy Iowa City Urologist Luke Brunkhorst, DO, will lead an open discussion about potential treatment for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).

The seminar, called “The Enlarged Prostate – Symptoms, Diagnosis and Treatment,” will take place virtually via Zoom on Wednesday, April 21 at 5:30 p.m. Those who are interested can sign up using this Zoom registration link. Registration is confidential to protect prospective patients’ information.

“Mercy Iowa City Urology is committed to providing patients with effective options to address their urology needs with the best patient experience,” Dr. Brunkhorst said. “The UroLift System has a strong safety profile and provides men suffering from an enlarged prostate a beneficial first-line treatment alternative to drug therapy or more invasive surgery. Importantly, the UroLift System provides rapid relief from BPH symptoms and improves the overall quality of life for our patients.”

Dr. Brunkhorst is certified by the American Osteopathic Board of Surgery – Urology and has special interests in robotic and minimally invasive surgery and performs UroLift procedures. The UroLift System is a minimally invasive procedure that may help relieve symptoms to allow patients to return quickly to normal activities.

BPH, also known as an enlarged prostate, is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep and decreased quality of life. Data estimates more than 42 million men in the U.S. are affected by BPH.


About Mercy Iowa City

Mercy Iowa City is an acute care hospital and regional referral center for southeast Iowa. Mercy has received: the Centers for Medicare and Medicaid (CMS) 5 Star Rating as a Top 2% of all hospitals for the 4th consecutive year, the only hospital in Iowa to do so; the Fortune IBM/Watson Health 100 Top Hospital ranking; the accredited Chest Pain Center with the American Heart Association Gold Plus Achievement Award for Stroke Care; the Top 100 Community Hospitals Award in 2018 and 2019 from Becker’s Review; the Press Ganey Guardian of Excellence Award for Mercy’s Emergency Care Unit by achieving 95 percent for patient experience for 13 consecutive years; and the Center of Distinction Award from Healogics for Mercy’s Wound and Vein Center. Mercy has 234 acute care beds, 25 private rooms for outpatient surgery, a 26-bed nursery with Level II Neonatal Intensive Care Unit, 28 primary and specialty care clinics, a medical staff of 250 physicians representing all major medical specialties and most subspecialties, and 1,350 employees. It was founded by the Sisters of Mercy in 1873 and became an affiliate of MercyOne in 2017. To learn more visit www.mercyiowacity.org. 

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function.*1,2 Patients also experienced significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.2 The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. Over 175,000 men have been treated with the UroLift System worldwide.** Learn more at www.UroLift.com.

* No instances of new, sustained erectile or ejaculatory dysfunction in the LIFT pivotal study

** Management estimate based on product sales and average units per procedure.